Lymphoma Clinical Trials

Norton Cancer Institute is at the forefront of cancer treatment research. As principal investigators on numerous trials, our specialist physicians have access to innovative treatments.

Learn more about participating in a clinical trial at Norton Healthcare.

Active lymphoma trials at Norton Cancer Institute include:

B-Cell Non-Hodgkin Lymphoma (NHL)

A Phase 2 Study of Lisocabtagene Maraleucel (JCAR017) as Second-Line Therapy in Adult Patients with Aggressive B-cell NHL (017006)

Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

A Phase 3, Randomized Study of Zanubrutinib (BGB-3111) Compared with Ibrutinib in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

Diffuse Large B-cell Lymphoma (DLBCL)

A Randomized Phase 3 Study to Evaluate the efficacy and Safety of Enzastaurin Plus R-CHOP Versus R-CHOP in Treatment-Naïve Subjects with High-Risk Diffuse Large B-Cell Lymphoma Who Possess the Novel Genomic Biomarker DGM1. (ENGINE Study)

Diffuse Large B-cell Lymphoma (DLBCL)

A Phase 1b Open-Label Study to Evaluate the Safety and Antitumor Activity of Loncastuximab Tesirine and Ibrutinib in Patients with Advanced Diffuse Large B-Cell Lymphoma or Mantle Cell Lymphoma

Follicular Lymphoma

A Multicenter, Randomized, Double-blind, Placebo-controlled Phase 3 Study of the Bruton’s Tyrosine Kinase (BTK) Inhibitor, Ibrutinib, in Combination with Rituximab versus Placebo in Combination with Rituximab in Treatment Naïve Subjects with Follicular Lymphoma

Hodgkin Lymphoma

Hodgkin Lymphoma Molecular Profiling and Clinical Outcomes in U.S. Community Oncology

Lymphoma

A Phase 3, Randomized, Double-blind, Placebo-controlled, Multicenter Study of Bendamustine and Rituximab (BR) Alone Versus in Combination with Acalabrutinib (ACP-196) in Subjects with Previously Untreated Mantle Cell Lymphoma

Lymphoma

A PHASE 1/2A OPEN-LABEL, MULTI-DOSE, MULTI-CENTER ESCALATION AND EXPLORATORY STUDY OF CERDULATINIB(PRT062070) IN PATIENTS WITH RELAPSED/REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA (CLL)/SMALL LYMPHOCYTIC LYMPHOMA (SLL) OR B-CELL or T-CELL NON-HODGKIN LYMPHOMA (NHL)

Lymphoma

A Phase 2b Randomized Study to Assess the Efficacy and Safety of the Combination of Ublituximab + TGR-1202 with or without Bendamustine and TGR-1202 alone in Patients with Previously Treated Non-Hodgkin’s Lymphoma

Lymphoma

A PHASE Ib/II STUDY EVALUATING THE SAFETY AND EFFICACY OF OBINUTUZUMAB IN COMBINATION WITH IDASANUTLIN AND VENETOCLAX IN PATIENTS WITH RELAPSED OR REFRACTORY FOLLICULAR LYMPHOMA OR DIFFUSE LARGE B-CELL LYMPHOMA

Lymphoma

Extended treatment protocol for subjects continuing to benefit from Ibrutinib after completion of Ibrutinib (PCI-32965) clinical trials.

Non-Hodgkin’s Lymphoma

Open-label, 2-arm, randomized, controlled Phase III trial of intravenous PI3K inhibitor copanlisib as monotherapy and in combination with rituximab, compared to rituximab monotherapy, in subjects with indolent B-cell non-Hodgkin lymphoma

Non-Hodgkin’s Lymphoma

A phase I/II study of lutetium (177Lu)-lilotomab satetraxetan (Betalutin®) antibodyradionuclide-conjugate for treatment of relapsed non-Hodgkin lymphoma

Non-Hodgkin’s Lymphoma

PRISM: A Platform Protocol for the Treatment of Relapsed/Refractory Aggressive Non-Hodgkin’s Lymphoma

Small Cell Lung Cancer (SCLC)

A Phase 1 Dose Escalation and Expanded Cohort Study of PF-06821497 in the treatment of adult patients with Relapsed/Refractory Small Cell Lung Cancer (SCLC), Castration Resistant Prostate Cancer (CRPC), and Follicular Lymphoma (FL)

T-Cell Lymphoma

Open label, Phase I/II study to evaluate the safety and efficacy of Tenalisib (RP6530), a novel PI3K ?/? dual inhibitor given in combination with a histone deacetylase (HDAC) inhibitor, Romidepsin in adult patients with relapsed/refractory […]

Cancer – 4673

Appointments

Cancer care that isn’t too far from home.

(502) 629-HOPE (4673)


Request an Appointment Online

Clinical trials

Clinical Trials

Learn more about clinical trials at Norton Healthcare
(502) 629-3501

Using vaccines to treat brain cancer: 4 things to know about this immunotherapy trial

Immunotherapy is a method of treating cancer, and new immune treatments are being studied across the country. Norton Cancer Institute is participating in a clinical trial conducted by AIVITA Biomedical Inc. to study whether a […]

Read Full Story

Why do I ride in Bike to Beat Cancer? Because I miss you, Rhonda

Ever have that work friend that turns into a real friend? Rhonda Hoffman was that real friend. We met not long after I moved here from Cincinnati for a career change. After several years, we […]

Read Full Story

Thomas M. Woodcock, M.D., to retire; pioneered cancer care in Louisville and Southern Indiana

Thomas M. Woodcock, M.D., came to Louisville in 1981 and was one of four founders of what is now Norton Cancer Institute. After almost 40 years as a medical oncologist, Dr. Woodcock plans to retire […]

Read Full Story

New dad gets ependymoma brain tumor diagnosis one day after son’s birth

March 2016 was a life-changing time for the Davis family. On March 23, Matt Davis and his wife, Hailey, celebrated the birth of their son, Finley. The next day, Matt learned he had a rare […]

Read Full Story

Cancer fighting food: Norton Cancer Institute nutritionists explain what you need to know

There’s a lot of information floating around about food and nutrition and how these contribute to your risk for disease, including cancer. Sorting through the news and research, some of it conflicting, can be confusing […]

Read Full Story
Related Stories

Using vaccines to treat brain cancer: 4 things to know about this immunotherapy trial

Immunotherapy is a method of treating cancer, and new immune treatments are being studied across the country. Norton Cancer Institute is participating in a clinical trial conducted by AIVITA Biomedical Inc. to study whether a […]

Read Full Story

Why do I ride in Bike to Beat Cancer? Because I miss you, Rhonda

Ever have that work friend that turns into a real friend? Rhonda Hoffman was that real friend. We met not long after I moved here from Cincinnati for a career change. After several years, we […]

Read Full Story

Thomas M. Woodcock, M.D., to retire; pioneered cancer care in Louisville and Southern Indiana

Thomas M. Woodcock, M.D., came to Louisville in 1981 and was one of four founders of what is now Norton Cancer Institute. After almost 40 years as a medical oncologist, Dr. Woodcock plans to retire […]

Read Full Story

New dad gets ependymoma brain tumor diagnosis one day after son’s birth

March 2016 was a life-changing time for the Davis family. On March 23, Matt Davis and his wife, Hailey, celebrated the birth of their son, Finley. The next day, Matt learned he had a rare […]

Read Full Story

Cancer fighting food: Norton Cancer Institute nutritionists explain what you need to know

There’s a lot of information floating around about food and nutrition and how these contribute to your risk for disease, including cancer. Sorting through the news and research, some of it conflicting, can be confusing […]

Read Full Story

Search our entire site.

Schedule an Appointment

Select an appointment date and time from available spots listed below.